Summary
Background Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture.
Methods This is a pragmatic multicenter, randomized, double-blind, placebo-controlled trial assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients.
Clinically healthy physicians, nurses, kinesiologists and others medical providers were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days.
The primary end point was clinical COVID-19, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322).
Findings A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics.
The incidence of COVID19 was significantly lower in the I-C group compared to placebo (1·0% vs 5·0%) (Odds Ratio 0·19 (95% confidence interval 0·05 to 0·77; p= 0·03). Workday loss in placebo group compared to I-Cc were 1.6% days / person (95% ci, 1.0 to 2.2); p <0.0001
There were no differences in the incidence of adverse events across the two groups (17·3% in the I-C group and 15·2% in the placebo group, p= 0·5).
Interpretation I-C showed significant efficacy in preventing SARS-Cov-2 infection in hospital personnel dedicated to care patients with COVID-19 disease.
Evidence before this study We searched PubMed for research articles published up to February 14, 2021, with no language restrictions, using the terms “SARS-CoV-2” or “COVID-19”, “prevention”, “clinical trial”, and “prophylaxis”. Except for studies on vaccines we only found three peer-reviewed publications available on the efficacy of Hydroxycholoquine to prevent COVID-19 disease in individuals at risk of exposure. Hydroxychloroquine did not prevent COVID-19 used as pre or postexposure prophylaxis. We also did not find results from clinical trials on the efficacy of carrageenan in the prevention or treatment of cOVID-19.
Added value of this study We report the clinical efficacy of a nasal spray with Iota-Carrageenan for the prevention of COVID-19 disease in a randomised, double-blind, placebo-controlled, multicentre study in República Argentina, including 394 participants.
Implications of all the available evidence A simple intervention such as the administration of a nasal spray with Iota-Carrageenan, in addition to hand hygiene, use of personal protective equipment and social distancing, could provide additional protection until vaccines can be administered to the majority of the population.
Competing Interest Statement
JMF and ML reports personal fees from Laboratorio Pablo Cassara, outside the submitted work.
Clinical Trial
NCT04521322
Funding Statement
The study did not received support for hospitals, staff or patients involved. Publication and administrative costs were supported by: Programa de articulacion y fortalecimiento federal de las capacidades en ciencia y tecnologia COVID-19, Proyecto CABA 20. Ministerio de Ciencia, Tecnologia e Innovacion, Argentina. Laboratorio Pablo Cassara free provided the drug and placebo samples. Acknowledgements: We thank the participating hospitals, their staff and persons included in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite de Bioetica Hospital Interzonal General de Agudos Eva Peron de San Martin. General San Martin bioeticahospitalevaperon@hotmail.com Coordinador:Dr Jorge Manrique Comite de Etica Hospital Alta Complejidad El Cruce. Florencio Varela comitedeetica@hospitalelcruce.org Coordinador: Dra Soledad Giargei Pintos
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* CARR-COV2 Trial Group collaborators are listed at the end of the manuscript
Data Availability
The data supporting the study findings are available within the paper.
